<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056209</url>
  </required_header>
  <id_info>
    <org_study_id>KL1333_101</org_study_id>
    <nct_id>NCT03056209</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation, Phase I Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yungjin Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yungjin Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this First In Human study is to investigate the safety and tolerability of
      KL1333 after a single oral dose and to investigate the pharmacokinetic characteristics of
      KL1333 after a single oral dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Actual">April 16, 2018</completion_date>
  <primary_completion_date type="Actual">April 16, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of reported adverse events</measure>
    <time_frame>from day 1 to day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of KL1333</measure>
    <time_frame>from day 1 to day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of KL1333</measure>
    <time_frame>from day 1 to day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) of KL1333</measure>
    <time_frame>from day 1 to day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>MELAS Syndrome</condition>
  <condition>Mitochondrial Respiratory Chain Deficiencies</condition>
  <arm_group>
    <arm_group_label>KL1333 25mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KL1333 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KL1333 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KL1333 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KL1333 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KL1333 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KL1333 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL1333 25 mg</intervention_name>
    <description>oral administration, single dose, 25 mg 1 tab</description>
    <arm_group_label>KL1333 25mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL1333 50 mg</intervention_name>
    <description>oral administration, single dose, 25 mg 2 tabs</description>
    <arm_group_label>KL1333 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL1333 100 mg</intervention_name>
    <description>oral administration, single dose, 100 mg 1 tab</description>
    <arm_group_label>KL1333 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL1333 200 mg</intervention_name>
    <description>oral administration, single dose, 100 mg 2 tabs</description>
    <arm_group_label>KL1333 200mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL1333 400 mg</intervention_name>
    <description>oral administration, single dose, 100 mg 4 tabs</description>
    <arm_group_label>KL1333 400mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL1333 600 mg</intervention_name>
    <description>oral administration, single dose, 100 mg 6 tabs</description>
    <arm_group_label>KL1333 600mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KL1333 800 mg</intervention_name>
    <description>oral administration, single dose, 100 mg 8 tabs</description>
    <arm_group_label>KL1333 800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral administration, placebo</description>
    <arm_group_label>KL1333 25mg</arm_group_label>
    <arm_group_label>KL1333 50mg</arm_group_label>
    <arm_group_label>KL1333 100mg</arm_group_label>
    <arm_group_label>KL1333 200mg</arm_group_label>
    <arm_group_label>KL1333 400mg</arm_group_label>
    <arm_group_label>KL1333 600mg</arm_group_label>
    <arm_group_label>KL1333 800mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19 - 45 years of age at the time of screening

          -  Subjects weighing ≥55 and ≤90 kg with BMI between 18 and 27 kg/m2

          -  Subjects who agreed to voluntarily participate in this study and comply with all the
             study requirements by signing informed consent form after being informed of the nature
             of this study and understanding all aspects of this study

        Exclusion Criteria:

          -  History of clinically significant hepatic, renal, neurologic, immunologic,
             respiratory, endocrine disease or hematologic•oncologic disease, cardiovascular,
             psychiatric disease

          -  History of disease or surgery of the gastrointestinal tract that could interfere with
             kinetics of the study drug. Simple hernia repair or appendectomy are excepted.

          -  History of clinically significant or relevant allergy/hypersensitivity

          -  Blood AST (SGOT), ALT (SGPT) &gt;1.5 of upper limit

          -  eGFR value of ≤90mL/min/1.73m2

          -  Systolic blood pressure of &lt;100 mmHg or &gt;160 mmHg

          -  Diastolic blood pressure of &lt;60 mmHg or &gt;100 mmHg

          -  Any abnormalities in 12-lead ECG at screening visit

          -  Subjects who showed positive result in drug abuse tests, or who has history of drug
             abuse within 60 days prior to the time of screening

          -  Subjects who took prescribed medications or oriental medicine within 14 days or
             over-the-counter (OTC) medications or vitamins within 7 days prior to the dose of the
             study drug (however, the subject can be included if other criteria are met according
             to the discretion of the investigator)

          -  Subjects who were administered any investigational products within 3 months from the
             first dose of the study drug

          -  Subjects who have donated whole blood (60 days) or partial blood (30 days), or
             received blood transfusion

          -  Subjects who have had alcohol consistently (&gt;21units/week, 1unit=10 g of pure alcohol)
             or who is not able to stop drinking alcohol throughout the study period

          -  Subjects who have smoked until 90 days prior to the study initiation or who are not
             able to stop smoking throughout the study period

          -  Subjects who are not able to stop taking grapefruit/caffeine from 3 days prior to the
             first dose of the study drug throughout the study period

          -  Subjects who plan for pregnancy during the study period or who are not able to use
             established contraceptive method

          -  Subject who judged not eligible for study participation by investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, MD., MBA</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitochondrial DNA tRNALeu(UUR) m.3243A&lt;G Mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MELAS Syndrome</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

